These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 30355943

  • 1. FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway.
    Huang T, Liu D, Wang Y, Li P, Sun L, Xiong H, Dai Y, Zou M, Yuan X, Qiu H.
    Cell Physiol Biochem; 2018; 50(4):1332-1345. PubMed ID: 30355943
    [Abstract] [Full Text] [Related]

  • 2. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway.
    Zeng L, Liao Q, Zou Z, Wen Y, Wang J, Liu C, He Q, Weng N, Zeng J, Tang H, Fang R, Lei Z, Tang Z, Yang X, Cui S.
    Cell Physiol Biochem; 2018; 51(3):1221-1236. PubMed ID: 30481766
    [Abstract] [Full Text] [Related]

  • 3. The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.
    Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, Weber H, Letelier P, Bellolio E, Villaseca M, Garcia P, Roa JC.
    Virchows Arch; 2014 Jul; 465(1):25-33. PubMed ID: 24844205
    [Abstract] [Full Text] [Related]

  • 4. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H, Liu Q, Tang J, Xie Y, Xu X, Huang R, Zhang Y, Jin K, Sun B.
    Cell Physiol Biochem; 2017 Jul; 41(6):2289-2306. PubMed ID: 28456796
    [Abstract] [Full Text] [Related]

  • 5. CEACAM6 promotes gastric cancer invasion and metastasis by inducing epithelial-mesenchymal transition via PI3K/AKT signaling pathway.
    Zang M, Zhang B, Zhang Y, Li J, Su L, Zhu Z, Gu Q, Liu B, Yan M.
    PLoS One; 2014 Jul; 9(11):e112908. PubMed ID: 25398131
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H, Lu J, Tang J, Chen S, He K, Jiang X, Jiang W, Teng L.
    BMC Cancer; 2017 Mar 14; 17(1):191. PubMed ID: 28292264
    [Abstract] [Full Text] [Related]

  • 9. Circular RNA hsa_circ_0010882 promotes the progression of gastric cancer via regulation of the PI3K/Akt/mTOR signaling pathway.
    Peng YK, Pu K, Su HX, Zhang J, Zheng Y, Ji R, Guo QH, Wang YP, Guan QL, Zhou YN.
    Eur Rev Med Pharmacol Sci; 2020 Feb 14; 24(3):1142-1151. PubMed ID: 32096170
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Celastrus Orbiculatus Extracts Inhibit the Metastasis through Attenuating PI3K/Akt/mTOR Signaling Pathway in Human Gastric Cancer.
    Qian Y, Yan Y, Lu H, Zhou T, Lv M, Fang C, Hou J, Li W, Chen X, Sun H, Li Y, Wang Z, Zhao N, Gu Y, Ding Y, Liu Y.
    Anticancer Agents Med Chem; 2019 Feb 14; 19(14):1754-1761. PubMed ID: 31364518
    [Abstract] [Full Text] [Related]

  • 13. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
    Zhang J, Wong CC, Leung KT, Wu F, Zhou Y, Tong JHM, Chan RCK, Li H, Wang Y, Yan H, Liu L, Wu WKK, Chan MWY, Cheng ASL, Yu J, Wong N, Lo KW, To KF, Kang W.
    Oncogene; 2020 Oct 14; 39(43):6647-6663. PubMed ID: 32934314
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT.
    Sun C, Tao Y, Gao Y, Xia Y, Liu Y, Wang G, Gu Y.
    Biomed Pharmacother; 2018 Feb 14; 98():416-423. PubMed ID: 29278851
    [Abstract] [Full Text] [Related]

  • 16. miR-5590-3p inhibited tumor growth in gastric cancer by targeting DDX5/AKT/m-TOR pathway.
    Wu N, Han Y, Liu H, Jiang M, Chu Y, Cao J, Lin J, Liu Y, Xu B, Xie X.
    Biochem Biophys Res Commun; 2018 Sep 10; 503(3):1491-1497. PubMed ID: 30029874
    [Abstract] [Full Text] [Related]

  • 17. ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer.
    Du W, Wang S, Zhou Q, Li X, Chu J, Chang Z, Tao Q, Ng EK, Fang J, Sung JJ, Yu J.
    Oncogene; 2013 Jul 11; 32(28):3319-28. PubMed ID: 22907434
    [Abstract] [Full Text] [Related]

  • 18. ACTL8 Promotes the Progression of Gastric Cancer Through PI3K/AKT/mTOR Signaling Pathway.
    Yu W, Zhang Q, Ali M, Chen B, Sun Q, Wang D.
    Dig Dis Sci; 2024 Oct 11; 69(10):3786-3798. PubMed ID: 39322809
    [Abstract] [Full Text] [Related]

  • 19. Huachansu Capsule inhibits the proliferation of human gastric cancer cells via Akt/mTOR pathway.
    Ni T, Wang H, Li D, Tao L, Lv M, Jin F, Wang W, Feng J, Qian Y, Sunagawa M, Liu Y.
    Biomed Pharmacother; 2019 Oct 11; 118():109241. PubMed ID: 31351435
    [Abstract] [Full Text] [Related]

  • 20. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Zhang L, Ji J, Gavine PR, Zhang J, Kilgour E, Zhang X, Ji Q.
    Clin Cancer Res; 2013 May 01; 19(9):2572-83. PubMed ID: 23493349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.